Liver Disease Clinical Trials in Chicago

Showing 61-80 of 90 trials

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

NCT01529268

CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate delayed-release capsules will result in improvement in liver disease severity.

Nonalcoholic Fatty Liver Disease (NAFLD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)169 participantsStarted Jun 2012

San Diego, California, United States • San Francisco, California, United States • Atlanta, Georgia, United States +7 more locations

COMPLETEDPhase 32.2 miles

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

NCT01473524

The main objectives of the study were to assess the effects of Obeticholic Acid (OCA) on serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint and on safety in participants with primary biliary cirrhosis (PBC).

Primary Biliary Cirrhosis

Intercept Pharmaceuticals217 participantsStarted Jan 2012

Sacramento, California, United States • San Diego, California, United States • Aurora, Colorado, United States +56 more locations

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Liver Disease Trials in Other Cities

The Patient-Reported Outcomes Project of HCV-TARGET

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

Adult-to-Adult Living Donor Liver Transplantation Study

A Study of IDN-6556 in Subjects With Liver Cirrhosis

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

Other Conditions in Chicago